Results 161 to 170 of about 53,966 (229)

Complete Response to the Combination of Immunotherapy and Targeted Therapy in Stage IV Nasal Adenocarcinoma of a Dog: A Case Report

open access: yesVeterinary Medicine and Science, Volume 12, Issue 2, March 2026.
The combination therapy of anti‐PD‐1 and TOC showed good therapeutic effects in this case of canine nasal adenocarcinoma, underscoring the potential of combining immunotherapy with targeted therapy in cases where single‐agent treatments fail. Combination therapy may enhance tumour growth inhibition by regulating the tumour immune microenvironment.
Yi Hu   +6 more
wiley   +1 more source

Psammaplysene D overcomes sorafenib resistance in liver cancer by targeting FGFR4/CYP26A1-retinoic acid axis to drive ferroptosis. [PDF]

open access: yesJ Exp Clin Cancer Res
Yang T   +11 more
europepmc   +1 more source

Drug Delivery Systems for Resiquimod to Control Myeloid‐Derived Suppressor Cells in Cancer Immunotherapy

open access: yesWIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.
Myeloid‐derived suppressor cells (MDSCs) are key contributors to cancer immunotherapy failure and major targets in new therapeutic strategies. We highlight therapeutic approaches to counteract their immunosuppressive functions and discuss recent efforts to optimize drug delivery for controlling MDSCs, focusing on resiquimod as a representative drug ...
Yanying He, Yoon Yeo
wiley   +1 more source

Targeting SPP1‐CD44‐Hedgehog Axis Elicits Therapeutic Effects in Hepatocellular Carcinoma by Suppressing Intratumoral Fibrosis

open access: yesCancer Science, Volume 117, Issue 3, Page 670-682, March 2026.
SPP1 was identified as a key driver of intratumoral fibrosis and hepatocellular carcinoma (HCC) progression through transcriptomic, histological, and functional analyses. Mechanistically, SPP1 promotes HSC activation and fibrosis via the SPP1–CD44–GLI1 axis, and pharmacologic inhibition of Hedgehog signaling effectively reduces tumor growth and ...
Atsushi Nara   +16 more
wiley   +1 more source

Primary and Secondary Grzybowski’s Generalized Eruptive Keratoacanthoma: A New Perspective on Management, Clinical Features, and Prognosis

open access: yesInternational Journal of Dermatology, Volume 65, Issue 3, Page 456-463, March 2026.
ABSTRACT Grzybowski's generalized eruptive keratoacanthoma (GEKA) is a rare variant of keratoacanthomas, characterized by hundreds to thousands of lesions, accompanied by pruritus, mucosal involvement, and comorbidities. Our aim was to analyze the clinical presentation, associated comorbidities, treatment strategies, and outcomes of GEKA.
Nicholas Florin Kormos   +6 more
wiley   +1 more source

Sex Differences in Cancer Immunotherapy—Clinical Evidence and Mechanisms With a Focus on NSCLC

open access: yesImmunological Reviews, Volume 338, Issue 1, March 2026.
ABSTRACT Accumulating evidence suggests that the immune system shows subtle but relevant differences between men and women. These differences may have an impact on cancer development and TME composition as well as responses to and adverse events elicited by immunotherapies.
Eva Krieghoff‐Henning   +4 more
wiley   +1 more source

Regulation of Autophagy and Metabolism in Hepatocellular Carcinoma: Involvement of Wnt‐β‐Catenin Pathway

open access: yesJournal of Cellular and Molecular Medicine, Volume 30, Issue 5, March 2026.
ABSTRACT Most cancer cells rely on aerobic glycolysis to support uncontrolled proliferation and evade apoptosis and switch to glutamine metabolism to survive under hypoxic conditions. In hepatocellular carcinoma (HCC), the Wnt/β‐catenin pathway acts as a critical driver of metabolic reprogramming and stemness, primarily by enhancing aerobic glycolysis ...
Sanjit K. Roy   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy